Skip to main content
. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473

Figure 2.

Box plots showing anti-Spike IgG avidity for various groups over time. Panel A represents 1 month, and Panel B represents 6 months post-vaccination. Groups include Healthy Control, Multiple Myeloma, Non-MM Hematological, and Solid, with differences across two, three, and four doses. The geometric mean and confidence intervals are provided. Statistical significance is indicated with p-values and asterisks.

Anti-SARS-CoV-2 spike IgG avidity post vaccination in serum samples from cancer and healthy cohorts. Comparison of serum anti-spike IgG avidity in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts 1-month (A) and 6-months (B) post-vaccination. Anti-spike IgG avidity was presented as Geometric Mean (GM) with 95% confidence intervals (95% CI). Box plots show median (horizontal bar), the first and third quartiles. Differences assessed by non-parametric Wilcoxon rank sum test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.